Immucell (ICCC) Return on Capital Employed (2011 - 2026)
Immucell's (ICCC) quarterly Return on Capital Employed came in at 4.11% in Q4 2025, up 817.0% YoY from 0.45% in Q4 2024, and down 25.51% on a QoQ basis from 5.51% in Q3 2025.
Immucell (ICCC) Return on Capital Employed (2011 - 2026) Analysis & Trends
Immucell (ICCC) has 15 years of Return on Capital Employed data on file, last reported at 4.11% in Q4 2025.
- Quarterly Return on Capital Employed rose 817.0% year-over-year to 4.11% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 4.11% (up 817.0% YoY) and the FY2025 annual result came in at 4.14%, up 824.0% from the prior year.
- Return on Capital Employed slipped to 4.11% in Q4 2025, from 5.51% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 5.51% in Q3 2025 to a low of 15.58% in Q3 2023.
- A 5-year average of 3.88% and a median of 3.35% in 2024 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2023 — Return on Capital Employed sank 1560 bps — and 2025, when it surged 1173 bps.
- Tracing ICCC's Return on Capital Employed over 5 years: stood at 0.62% in 2021, then plunged by 978 bps to 5.4% in 2022, then sank by 120 bps to 11.87% in 2023, then surged by 66 bps to 4.06% in 2024, then surged by 201 bps to 4.11% in 2025.
- The last three Return on Capital Employed figures came in at 4.11% (Q4 2025), 5.51% (Q3 2025), and 4.16% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 26.09% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -50.93% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 7.88% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -6.85% |
| 10 | Immucell | 92.01 Mn | 83.15 Mn | 2.44 Mn | 6.14% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.14% |
| Dec 31, 2025 | 4.11% |
| Sep 30, 2025 | 5.51% |
| Jun 30, 2025 | 4.16% |
| Mar 31, 2025 | -0.54% |
| Dec 31, 2024 | -4.06% |
| Sep 30, 2024 | -5.85% |
| Jun 30, 2024 | -7.58% |
| Mar 31, 2024 | -7.11% |
| Dec 31, 2023 | -11.87% |
| Sep 30, 2023 | -15.58% |
| Jun 30, 2023 | -14.76% |
| Mar 31, 2023 | -12.76% |
| Dec 31, 2022 | -5.40% |
| Sep 30, 2022 | -1.20% |
| Jun 30, 2022 | 0.84% |
| Mar 31, 2022 | 2.80% |
| Dec 31, 2021 | 0.62% |
| Sep 30, 2021 | -1.25% |
| Jun 30, 2021 | -2.64% |